Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. (symbol: RVPH) is a late-stage pharmaceutical company based in San Jose, California. Located at 5941 Optical Ct, the company is renowned for discovering, developing, and seeking to commercialize innovative therapeutics for various diseases. Their primary focus areas include the central nervous system, inflammatory, and cardiometabolic diseases.
Leveraging a unique chemical genomics-driven technology platform and proprietary chemistry, Reviva aims to revolutionize treatment options. Their pipeline currently includes two prominent drug candidates:
- Brilaroxazine (RP5063): This versatile drug is intended to address multiple neuropsychiatric conditions such as schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis.
- RP1208: Another promising candidate in their pipeline.
Reviva Pharmaceuticals continues to make strides with recent achievements and ongoing projects that keep the company at the forefront of medical innovation. For more detailed and up-to-date information, please visit their website or contact their corporate and investor relations representatives.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) will host a webinar on May 2, 2023, at 11:00 AM ET featuring KOL Larry Ereshefsky, PharmD, discussing brilaroxazine (RP5063), a serotonin-dopamine modulator in late development for schizophrenia. The event will cover the unmet medical need in schizophrenia treatment and Reviva's clinical trial data, including the ongoing RECOVER Phase 3 trial. Brilaroxazine has exhibited significant efficacy in a Phase 2 study, demonstrating improvements in PANSS total scores and meeting safety endpoints. Furthermore, it has potential for use in other neuropsychiatric and pulmonary conditions, having received Orphan Drug Designation from the FDA for certain indications. This webinar aims to provide insights on the treatment landscape and sustainable advancements in psychiatric and inflammatory therapies.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry from April 27-29, 2023, in San Diego, CA. The presentation, titled "Brilaroxazine (RP5063), a novel serotonin-dopamine stabilizer, displays antipsychotic efficacy in rodents," will take place on April 29, 2023, from 5:00-7:00 PM PT.
Brilaroxazine is a drug candidate showing significant clinical promise for treating schizophrenia and related disorders. In Phase 2 studies, it met primary endpoints, demonstrating efficacy with no adverse effects on weight or metabolic parameters. Additionally, it has potential applications in pulmonary diseases like PAH and IPF, having received Orphan Drug Designation from the FDA. Reviva aims to pursue further development of brilaroxazine for various neuropsychiatric conditions.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will feature on The RedChip Money Report® on Bloomberg TV on April 22, 2023, at 7 p.m. ET. The interview includes insights from CEO Laxminarayan Bhat regarding the Company’s Phase 3 trial for schizophrenia and promising safety and efficacy results from the Phase 2 study. Reviva’s focus is on developing next-generation therapeutics to address unmet medical needs, with ongoing research on drug candidates like brilaroxazine (RP5063) and RP1208. Reviva holds composition of matter patents for both candidates in the U.S. and Europe. The RedChip Money Report® aims to provide investors with valuable information on small-cap investing and features various financial insights.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported financial results for the year ended December 31, 2022, highlighting significant progress towards brilaroxazine's NDA submission for treating schizophrenia. The pivotal Phase 3 RECOVER trial has enrolled over 50% of its 400 patients, with topline data expected mid-2023. The company reported a net loss of approximately $24.3 million, or $1.25 per share, compared to a loss of $8.5 million, or $0.58 per share in 2021. Cash and equivalents stood at $18.5 million as of December 31, 2022, sufficient to support operations through Q3 2023.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its CEO Laxminarayan Bhat will present at the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, California. The presentation will take place on March 13 at 3:00 p.m. PT. Reviva focuses on developing therapies for unmet medical needs, particularly in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Their pipeline includes drug candidates brilaroxazine (RP5063) and RP1208. For more details, visit the webcast link.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company, will have its Founder and CEO, Laxminarayan Bhat, present at the BIO CEO and Investor Conference from February 6–9, 2023 in New York. The presentation is scheduled for February 6 at 11:30 p.m. EST. Reviva focuses on developing therapies for unmet medical needs in central nervous system, cardiovascular, metabolic, and inflammatory diseases. Their pipeline includes drug candidates RP5063 (brilaroxazine) and RP1208, both with composition of matter patents in multiple regions.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced progress in its Phase 3 RECOVER trial for brilaroxazine, targeting schizophrenia, with top-line data expected in mid-2023. Approximately 40% of patients have been treated with no serious adverse events reported. The company secured $8.5 million in funding to support this trial. Additionally, they completed a drug-drug interaction study showing brilaroxazine's favorable safety profile. Reviva aims to explore other indications, representing a combined market opportunity exceeding $70 billion. Upcoming milestones include potential NDA submission in 2025.
FAQ
What is the current stock price of Reviva Pharmaceutcls Hldgs (RVPH)?
What is the market cap of Reviva Pharmaceutcls Hldgs (RVPH)?
What does Reviva Pharmaceuticals Holdings, Inc. specialize in?
Where is Reviva Pharmaceuticals Holdings, Inc. located?
What is Brilaroxazine (RP5063)?
What is the focus of Reviva's current pipeline?
What technology does Reviva use for drug development?
Who can be contacted for more information about Reviva Pharmaceuticals?
What other drug candidate is in Reviva's pipeline besides Brilaroxazine?
What are the therapeutic areas targeted by Reviva Pharmaceuticals?
How can I stay updated with Reviva Pharmaceuticals' latest news?
Who is the main contact for investor inquiries at Reviva Pharmaceuticals?
